Galapagos creates new warrant plan


MECHELEN, BELGIUM--(Marketwired - May 17, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG)announced todaythat its Board of Directors created 648,490 warrants under a new warrantplanfor the benefit of employees, directors and independent consultantsof theCompany and its subsidiaries.

On 16 May 2013, the Board of Directors of Galapagos approved the "WarrantPlan2013" within the framework of the authorized capital. Under this warrantplan,648,490 warrants were created, subject to acceptances.

The warrants created under Warrant Plan 2013 were offered on 16 May 2013,mainlyto employees of Galapagos and its subsidiaries and in secondary orderto itsdirectors and independent consultants. The offer of warrants todirectors hasbeen pre-approved by the Ordinary General Shareholders' Meetingheld on30 April 2013.

The warrants have an exercise term of eight years as of the date of theofferand have an exercise price of EUR19.38 (the average closing price of theshare onEuronext Brussels during the thirty days preceding date of the offer).Thewarrants are not transferable and can in principle not be exercised priorto theend of the third calendar year after the calendar year in which theyweregranted to the beneficiaries. Each warrant gives the right to subscribeto onenew Galapagos share. Should the warrants be exercised, Galapagos willapply forthe listing of the resulting new shares on a regulated stock market.Thewarrants as such will not be listed on any stock market.

To date, Galapagos' total share capital amounts to EUR160,474,357.19;the totalnumber of securities conferring voting rights is 29,665,159, which isalso thetotal number of voting rights (the "denominator"), and all securitiesconferringvoting rights and all voting rights are of the same category. The totalnumberof rights (warrants) to subscribe to not yet issued securities conferringvotingrights is 3,123.368, which equals the total number of voting rightsthat mayresult from the exercise of these warrants. Galapagos does nothave anyconvertible bonds or shares without voting rights outstanding.

About Galapagos

Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized innovel modes-of-action,with a large pipeline of four clinical, seven pre-clinical, and 30discoverysmall-molecule and antibody programs in cystic fibrosis,inflammation,antibiotics, metabolic disease, and other indications.GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatmentof rheumatoid arthritis and potentially other inflammatory diseases,about toenter Phase 2b studies in RA and Phase 2 studies in Crohn's disease.AbbVie andGalapagos signed a worldwide license agreement whereby AbbViewill beresponsible for further development and commercialization after Phase2b.Galapagos has another selective JAK1 inhibitor in Phase 2 in lupusandpsoriasis, GSK2586184 (formerly GLPG0778, in-licensed byGlaxoSmithKline in2012). GLPG0187 is a novel integrin receptor antagonist currently in aPhase1b patient study in metastasis. GLPG0974 is the first inhibitor of GPR43to beevaluated clinically for the treatment of IBD; this program is currentlyin aProof of Concept Phase 2 study.

The Galapagos Group, including fee-for-service companies BioFocus,Argenta andFidelta, has 800 employees and operates facilities in five countries,withglobal headquarters in Mechelen, Belgium. Further information

Galapagos forward-looking statements

This release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks,uncertainties and otherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements. Giventhese uncertainties, the reader is advised not to place any undue relianceonsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expressly disclaimsanyobligation to update any such forward-looking statements in this documenttoreflect any change in its expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.

Galapagos creates new warrant plan:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE[HUG#1702834]


Galapagos NV
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact

View Comments (0)

Recommended for You